Clinical trial · no report yet · Phase 2
NCT06361927
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
- NCT06361927 ↗
- Unknown
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- NSCLC
- Interventions
- SSGJ-707
- Arms
- cohort A：dose level 1 of SSGJ-707 · Experimental
- cohort A：dose level 2 of SSGJ-707 · Experimental
- cohort A：dose level 3 of SSGJ-707 · Experimental
- cohort B：dose level 1 of SSGJ-707 · Experimental
- cohort B：dose level 2 of SSGJ-707 · Experimental
- cohort B：dose level 3 of SSGJ-707 · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- ORR
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Start
- May 15, 2024
- Primary completion
- Jun 2025 (estimated)
- Results posted
- No
- Registry record
- NCT06361927 · updated May 16, 2024